BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Nabriva Therapeutics 

Leberstrasse 20

Vienna    1112  Austria
Phone: 43-0-1-74093-0 Fax: 43-0-1-74093-1900


SEARCH JOBS










 Company News
Forest Laboratories, Inc. (FRX) Coughs Up $25 Million for Nabriva Therapeutics's Phase II Antibacterial, Right to Take Over Company 6/1/2012 6:42:35 AM    More...
Nabriva Therapeutics Chooses TransPerfect Trial Interactive to Oversee Its Licensing Process 9/27/2011 10:42:28 AM    More...
Nabriva Therapeutics Presents Extended Phase II Results for Pleuromutilin Antibiotic BC-3781 9/19/2011 10:33:08 AM    More...
Nabriva Therapeutics Reports Positive Results from Phase II Trial of Pleuromutilin Antibiotic BC-3781 in ABSSSI 4/18/2011 10:48:33 AM    More...
Nabriva Therapeutics Completes Recruitment for Phase II of Pleuromutilin Antibiotic BC-3781 1/10/2011 10:51:34 AM    More...
Nabriva Therapeutics' Pleuromutilin Antibiotic BC-3781 Shows Therapeutic Potential for Skin and Lung Infections with both Oral and IV Dosing in Non-Clinical and Clinical Phase I Studies 9/10/2010 11:35:17 AM    More...
Nabriva Therapeutics Initiates Phase II Of Pleuromutilin Antibiotic BC-3781 6/2/2010 11:32:05 AM    More...
Nabriva Therapeutics Raises $22 Million 10/28/2009 7:25:29 AM    More...
Nabriva Therapeutics Initiates Clinical Phase I Trial of Pleuromutilin Antibiotic BC-3781 7/23/2009 1:45:38 PM    More...
Nabriva Therapeutics Appoints New Supervisory Board Member 5/7/2009 12:19:51 PM    More...
12